Tessera Therapeutics is a clinical-stage biopharmaceutical company developing engineered T cell therapies for cancer treatment, using proprietary non-viral transposon-based technology to equip T cells with novel receptors targeting cancer-associated antigens. The company operates in the oncology market, focusing on hematologic malignancies and solid tumors, with potential customers including healthcare systems and cancer treatment centers; its future revenue would derive from the sale of customized engineered T cell therapies at premium pricing, contingent on regulatory approval and successful commercialization. As a pre-revenue company, Tessera maintains internal manufacturing capabilities supplemented by third-party suppliers, and must navigate complex challenges around manufacturing scalability, process consistency, and supply chain reliability to bring its pipeline candidates to market.